共 50 条
- [41] A Randomized, Double-Blind, Parallel-Group, Phase III Study of Shortening the Dosing Interval of Subcutaneous Tocilizumab Monotherapy in RA Patients with an Inadequate Response to Subcutaneous Tocilizumab Every Other WeekARTHRITIS & RHEUMATOLOGY, 2016, 68Ogata, AtsushiTakagi, NobuhiroMiwa, Hiroko
- [42] Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2184 - +Edelman, Martin J.Wang, XiaofeiHodgson, LydiaCheney, Richard T.Baggstrom, Maria Q.Thomas, Sachdev P.Gajra, AjeetBertino, ErinReckamp, Karen L.Molina, JulianSchiller, Joan H.Mitchell-Richards, KishaFriedman, Paula N.Ritter, JonMilne, GingerHahn, Olwen M.Stinchcombe, Thomas E.Vokes, Everett E.
- [43] A non-inferiority randomized phase III trial of standard immunotherapy versus reduced dose intensity in responding patients with metastatic cancer: MOIO studyJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Gravis, GwenaelleOlive, DanielMarino, PatriciaPenault-Llorca, Frederique MadeleineDelord, Jean-PierreLamrani-Ghaouti, AssiaSimon, ClotildeSabatier, RenaudCiccolini, JosephBoher, Jean-Marie
- [44] FOLFOX4 With Cetuximab vs. UFOX With Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: The Randomized Phase II FUTURE StudyCLINICAL COLORECTAL CANCER, 2014, 13 (01) : 14 - U39Douillard, Jean-YvesZemelka, TomaszFountzilas, GeorgeBarone, CarloSchlichting, MichaelHeighway, JimEggleton, S. PeterSrimuninnimit, Vichien
- [45] A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13Metzenmacher, MartinKopp, Hans-GeorgGriesinger, FrankReinmuth, NielsSebastian, MartinSerke, MonikaWaller, Cornelius FlorianThomas, MichaelEggert, JochenSchmid-Bindert, GeraldHoiczyk, MathiasChristoph, Daniel ChristianKimmich, MartinDeuss, BurkhardSeifert, StephanieHeld, SwantjeSchuler, MartinHerold, ThomasBreitenbuecher, FrankEberhardt, Wilfried Ernst Erich
- [46] Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regoraferab (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)ANNALS OF ONCOLOGY, 2019, 30Argiles, G.Mulet Margalef, N.Valladares-Ayerbes, M.Vieitez de Prado, J.Gravalos, C.Garcia Alfonso, P.Santos, C.Tobena, M.Sastre, J.Benavides, M.Cano, T.Loupakis, F.Rodriguez Garrote, M.Rivera, F.Goldberg, R.Falcone, A.Bennouna, J.Ciardiello, F.Tabernero, J.Aranda, E.
- [47] A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Sternberg, Cora N.Saad, FredGraff, Julie NicolePeer, AvivitVaishampayan, Ulka N.Leung, EugeneRosenbaum, EliGurney, HowardEpstein, RichardDavis, Ian D.Wu, BingyanTrandafir, LuciaWagner, Volker JeanHussain, Maha
- [48] Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial)JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Ajani, Jaffer A.Abramov, MikhailBondar, VolodymyrBondarenko, IgorShparyk, Yaroslav V.Gorbunova, VeraAnatoliy, HontsaVinnyk, YuriyAlsina, MariaLazarev, SergeyFeliu, JaimeElme, AnneliEsko, VivianRosati, GerardoAbdalla, Kathia CristinaVerma, Udit N.Benedetti, Fabio M.Aoyama, TakekazuMizuguchi, HirokazuMakris, Lukas
- [49] Adjuvant Radiotherapy after breast conserving Surgery for Breast cancer: Hypofractionation with simultaneous integrated Boost vs. Standard Fractionation: a proposed multicenter randomized controlled Phase III Treatment optimization study (HYPOSIB)STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 : 34 - 35Dellas, K.Krockenberger, K.Vonthein, R.Koenig, IZiegler, A.Dunst, J.
- [50] Alliance A022102: Randomized phase III trial of mFOLFIRINOX plus /- nivolumab vs. FOLFOX plus /- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Park, HaeseongGeyer, Susan MichelleKlute, KelseyBleeker, JonathanKing, DanielStrickland, MatthewGoodrich, AustinCarlisle, DestinShergill, ArdamanO'Reilly, Eileen MaryMeyerhardt, Jeffrey A.Shah, Manish A.